Skip to content
MarketScale
‹ Back to IndustriesHealthcare

USP CLASS VI CERTIFICATION

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety. The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety.

The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for plastics and polymers that come in contact with patient tissue. For these materials, there are six classes, with VI being the most stringent. While the first five classifications are valuable for certain materials, Class VI is the most compatible for medical applications.

USP Class VI – Three Evaluations to Ensure Safety

For the USP Class VI, there are three tests that materials must meet to be deemed safe. There are four standards that these evaluations test: purity, strength, quality and consistency. Here are the three tests explained:

  • Acute Systemic Toxicity measures the toxicity and irritation when a sample of the material is administered orally, placed on the skin or inhaled. It is extracted in up to four solutions: saline, vegetable oil, alcohol saline and polyethylene glycol. The test model is then observed for three days to determine any ill effects.
  • Intracutaneous determines the material’s toxicity and localized irritation when it touches live skin. It is extracted using the same four solutions. Test and control sites are compared to see if there is any significant reaction.
  • Implantation assesses toxicity, infection and irritation of intramuscular These implantations are observed for five to seven days to determine if there is any negative response.

These tests focus on toxicity while evaluating temperature over specific time periods. If a material does meet rigorous USP Class VI standards, then it is likely to be accepted by the FDA and USDA. Class VI testing encompasses any kind of possible applications that include the standard polar and nonpolar extracts required for ISO 10993-12 for completed devices. It’s considered the gold standard for medical-grade raw materials.

The USP Class testing was initially intended for polymers but can also be used to test other materials that encounter patients. The Class labels are meant to represent real-world usage.

EVA from Presco Meets Class VI

EVA (ethylene-vinyl acetate), is a copolymer consisting of ethylene and vinyl acetate. This medical grade film is a soft, clear material that can be RF-welded to create medical solution containers and tubing sets.

With rising concerns regarding the use of PVC in medical applications, EVA has been found to be a suitable alternative for medical use. In fact, for medical bags, EVA is the preferred choice—it has proven track record spanning three decades of wide use in medical device applications, particularly in IV therapy.

Why Choose EVA?

  • 30% lighter than PVC for a better yield and lower shipping costs
  • EVA has better tear and burst strength
  • Exceptional sealing properties
  • Strong impact resistance and cold crack properties
  • Meets all regulatory requirements of the market
  • Bio-compatible as certified with USP Class VI testing
  • No plasticizers or chlorine
  • Printable for fill lines

Pres-Flex EVA is Presco’s first PVC-free manufacturing capability for engineered film. To learn more about USP Class VI certified EVA film from Presco, contact us today. Our team of experienced professionals can guide you through your organization’s unique needs to determine whether this highly-favored PVC alternative is appropriate for your manufacturing processes.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512